• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/12/21 6:11:58 AM ET
    $PPD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $PPD alert in real time by email
    SC 13G 1 d128142dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.    )*

     

     

    PPD, Inc.

    (Name of Issuer)

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

    69355F102

    (CUSIP Number)

    December 31, 2020

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed: specificity

     

    ☐

    Rule 13d-1(b)

     

    ☐

    Rule 13d-1(c)

     

    ☒

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 69355F102

     

      1.    

      Name of Reporting Person

     

      H&F Corporate Investors VII, Ltd.

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Cayman Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

       5.     

      Sole Voting Power

     

      77,118,535

       6.   

      Shared Voting Power

     

      0

       7.   

      Sole Dispositive Power

     

      77,118,535

       8.   

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      77,118,535

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      22.1%

    12.  

      Type of Reporting Person (See Instructions)

     

      CO

     

    2


    CUSIP No. 69355F102

     

      1.    

      Name of Reporting Person

     

      Hellman & Friedman Investors VII, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Cayman Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

       5.     

      Sole Voting Power

     

      77,118,535

       6.   

      Shared Voting Power

     

      0

       7.   

      Sole Dispositive Power

     

      77,118,535

       8.   

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      77,118,535

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      22.1%

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    3


    CUSIP No. 69355F102

     

      1.    

      Name of Reporting Person

     

      Hellman & Friedman Capital Partners VII L.P.

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Cayman Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

       5.     

      Sole Voting Power

     

      52,884,036

       6.   

      Shared Voting Power

     

      0

       7.   

      Sole Dispositive Power

     

      52,884,036

       8.   

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      52,884,036

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      15.1%

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    4


    CUSIP No. 69355F102

     

      1.    

      Name of Reporting Person

     

      Hellman & Friedman Capital Partners VII (Parallel), L.P.

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Cayman Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

       5.     

      Sole Voting Power

     

      20,244,387

       6.   

      Shared Voting Power

     

      0

       7.   

      Sole Dispositive Power

     

      20,244,387

       8.   

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      20,244,387

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      5.8%

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    5


    CUSIP No. 69355F102

     

      1.    

      Name of Reporting Person

     

      HFCP VII (Parallel-A), L.P.

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

       5.     

      Sole Voting Power

     

      3,630,740

       6.   

      Shared Voting Power

     

      0

       7.   

      Sole Dispositive Power

     

      3,630,740

       8.   

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      3,630,740

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      1.0%

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    6


    CUSIP No. 69355F102

     

      1.    

      Name of Reporting Person

     

      H&F Executives VII, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Cayman Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

       5.     

      Sole Voting Power

     

      359,372

       6.   

      Shared Voting Power

     

      0

       7.   

      Sole Dispositive Power

     

      359,372

       8.   

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      359,372

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      0.1%

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    7


    CUSIP No. 69355F102

     

      1.    

      Name of Reporting Person

     

      H&F Corporate Investors VIII, Ltd.

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Cayman Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

       5.     

      Sole Voting Power

     

      55,722,731

       6.   

      Shared Voting Power

     

      0

       7.   

      Sole Dispositive Power

     

      55,722,731

       8.   

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      55,722,731

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      15.9%

    12.  

      Type of Reporting Person (See Instructions)

     

      CO

     

    8


    CUSIP No. 69355F102

     

      1.    

      Name of Reporting Person

     

      Hellman & Friedman Investors VIII, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Cayman Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

       5.     

      Sole Voting Power

     

      55,722,731

       6.   

      Shared Voting Power

     

      0

       7.   

      Sole Dispositive Power

     

      55,722,731

       8.   

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      55,722,731

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      15.9%

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    9


    CUSIP No. 69355F102

     

      1.    

      Name of Reporting Person

     

      Hellman & Friedman Capital Partners VIII, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Cayman Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

       5.     

      Sole Voting Power

     

      35,622,429

       6.   

      Shared Voting Power

     

      0

       7.   

      Sole Dispositive Power

     

      35,622,429

       8.   

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      35,622,429

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      10.2%

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    10


    CUSIP No. 69355F102

     

      1.    

      Name of Reporting Person

     

      Hellman & Friedman Capital Partners VIII (Parallel), L.P.

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Cayman Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

       5.     

      Sole Voting Power

     

      15,987,409

       6.   

      Shared Voting Power

     

      0

       7.   

      Sole Dispositive Power

     

      15,987,409

       8.   

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      15,987,409

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      4.6%

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    11


    CUSIP No. 69355F102

     

      1.    

      Name of Reporting Person

     

      HFCP VIII (Parallel-A), L.P.

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

       5.     

      Sole Voting Power

     

      3,021,286

       6.   

      Shared Voting Power

     

      0

       7.   

      Sole Dispositive Power

     

      3,021,286

       8.   

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      3,021,286

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      0.9%

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    12


    CUSIP No. 69355F102

     

      1.    

      Name of Reporting Person

     

      H&F Executives VIII, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Cayman Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

       5.     

      Sole Voting Power

     

      934,469

       6.   

      Shared Voting Power

     

      0

       7.   

      Sole Dispositive Power

     

      934,469

       8.   

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      934,469

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      0.3%

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    13


    CUSIP No. 69355F102

     

      1.    

      Name of Reporting Person

     

      H&F Associates VIII, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group

      (a)  ☐        (b)  ☒

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Cayman Islands

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with

       5.     

      Sole Voting Power

     

      157,138

       6.   

      Shared Voting Power

     

      0

       7.   

      Sole Dispositive Power

     

      157,138

       8.   

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      157,138

    10.  

      Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      Less than 0.1%

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    14


    STATEMENT ON SCHEDULE 13G

    Pursuant to Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended (the “Act”), each of the persons listed below under Item 2 (each a “Reporting Person,” and collectively the “Reporting Persons”), have agreed to file one statement with respect to their beneficial ownership of common stock, par value $0.01 per share (“Common Stock”), of PPD, Inc. (the “Issuer”).

    Item 1.

    (a) Name of Issuer:

    PPD, Inc.

    (b) Address of Issuer’s Principal Executive Offices:

    929 North Front Street

    Wilmington, North Carolina 28401

    Item 2.

    (a) Name of Person Filing:

    H&F Corporate Investors VII, Ltd.

    Hellman & Friedman Investors VII, L.P.

    Hellman & Friedman Capital Partners VII, L.P.

    Hellman & Friedman Capital Partners VII (Parallel), L.P.

    HFCP VII (Parallel-A), L.P.

    H&F Executives VII, L.P.

    H&F Corporate Investors VIII, Ltd.

    Hellman & Friedman Investors VIII, L.P.

    Hellman & Friedman Capital Partners VIII, L.P.

    Hellman & Friedman Capital Partners VIII (Parallel), L.P.

    HFCP VIII (Parallel-A), L.P.

    H&F Executives VIII, L.P.

    H&F Associates VIII, L.P.

    (b) Address of Principal Business Office, or, if None, Residence:

    The principal business office for all persons filing:

    415 Mission Street, Suite 5700

    San Francisco, CA 94105

    (c) Citizenship:

    See Item 4 of each cover page.

    (d) Title of Class of Securities:

    Common stock, par value $0.01 per share.

    (e) CUSIP Number:

    69355F102


    Item 3.

    Not applicable.

    Item 4. Ownership.

    (a) Amount beneficially owned:

    See Item 9 of each cover page.

    The Reporting Persons beneficially own an aggregate of 132,841,266 shares of Common Stock. Hellman & Friedman Capital Partners VII, L.P. directly holds 52,884,036 shares of Common Stock, Hellman & Friedman Capital Partners VII (Parallel), L.P. directly holds 20,244,387 shares of Common Stock, HFCP VII (Parallel-A), L.P. directly holds 3,630,740 shares of Common Stock, H&F Executives VII, L.P. directly holds 359,372 shares of Common Stock, Hellman & Friedman Capital Partners VIII, L.P. directly holds 35,622,429 shares of Common Stock, Hellman & Friedman Capital Partners VIII (Parallel), L.P. directly holds 15,987,409 shares of Common Stock, HFCP VIII (Parallel-A), L.P. directly holds 3,021,286 shares of Common Stock, H&F Executives VIII, L.P. directly holds 934,469 shares of Common Stock, and H&F Associates VIII, L.P. directly holds 157,138 shares of Common Stock.

    The general partner of each of Hellman & Friedman Capital Partners VII, L.P., Hellman & Friedman Capital Partners VII (Parallel), L.P., HFCP VII (Parallel-A), L.P. and H&F Executives VII, L.P. (collectively, the “H&F VII Funds”) is Hellman & Friedman Investors VII, L.P. The general partner of Hellman & Friedman Investors VII, L.P. is H&F Corporate Investors VII, Ltd. The general partner of each of Hellman & Friedman Capital Partners VIII, L.P., Hellman & Friedman Capital Partners VIII (Parallel), L.P., HFCP VIII (Parallel-A), L.P., H&F Executives VIII, L.P. and H&F Associates VIII, L.P. (collectively, the “H&F VIII Funds”) is Hellman & Friedman Investors VIII, L.P. The general partner of Hellman & Friedman Investors VIII, L.P. is H&F Corporate Investors VIII, Ltd.

    A three member board of directors of each of H&F Corporate Investors VII, Ltd. and H&F Corporate Investors VIII, Ltd. has investment discretion over the shares held by the H&F VII Funds and the H&F VIII Funds, respectively. Each of the members of the boards of directors disclaims beneficial ownership of such shares.

    (b) Percent of class:

    See Item 11 of each cover page.

    The Reporting Persons beneficially own an aggregate of 132,841,266 shares of Common Stock representing 38.0% of the outstanding shares. The ownership percentages are calculated based upon 349,654,449 shares of Common Stock outstanding as October 26, 2020, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020, as filed with the Securities and Exchange Commission on October 28, 2020.

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    See Item 5 of each cover page.

    (ii) Shared power to vote or to direct the vote

    See Item 6 of each cover page.

    (iii) Sole power to dispose or to direct the disposition of

    See Item 7 of each cover page.

    (iv) Shared power to dispose or to direct the disposition of

    See Item 8 of each cover page.


    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

    Item 8. Identification and Classification of Members of the Group.

    Not applicable.

    Item 9. Notice of Dissolution of Group.

    Not applicable.

    Item 10. Certifications.

    Not applicable.


    SIGNATURES

    After reasonable inquiry and to the best of the knowledge and belief of the undersigned, the undersigned certify that the information set forth in this statement is true, complete and correct.

    Dated February 12, 2021

     

    H&F CORPORATE INVESTORS VII, LTD.
    By:  

    /s/ Trevor Watt

    Name:   Trevor Watt
    Title:   Vice President
    HELLMAN & FRIEDMAN INVESTORS VII, L.P.
    By:   H&F Corporate Investors VII, Ltd., its general partner
    By:  

    /s/ Trevor Watt

    Name:   Trevor Watt
    Title:   Vice President
    HELLMAN & FRIEDMAN CAPITAL PARTNERS VII, L.P.
    By:   Hellman & Friedman Investors VII, L.P., its general partner
    By:   H&F Corporate Investors VII, Ltd., its general partner
    By:  

    /s/ Trevor Watt

    Name:   Trevor Watt
    Title:   Vice President
    HELLMAN & FRIEDMAN CAPITAL PARTNERS VII (PARALLEL), L.P.
    By:   Hellman & Friedman Investors VII, L.P., its general partner
    By:   H&F Corporate Investors VII, Ltd., its general partner
    By:  

    /s/ Trevor Watt

    Name:   Trevor Watt
    Title:   Vice President


    HFCP VII (PARALLEL-A), L.P.
    By:   Hellman & Friedman Investors VII, L.P., its general partner
    By:   H&F Corporate Investors VII, Ltd., its general partner
    By:  

    /s/ Trevor Watt

    Name:   Trevor Watt
    Title:   Vice President
    H&F EXECUTIVES VII, L.P.
    By:   Hellman & Friedman Investors VII, L.P., its general partner
    By:   H&F Corporate Investors VII, Ltd., its general partner
    By:  

    /s/ Trevor Watt

    Name:   Trevor Watt
    Title:   Vice President
    H&F CORPORATE INVESTORS VIII, LTD.
    By:  

    /s/ Trevor Watt

    Name:   Trevor Watt
    Title:   Vice President
    HELLMAN & FRIEDMAN INVESTORS VIII, L.P.
    By:   H&F Corporate Investors VIII, Ltd., its general partner
    By:  

    /s/ Trevor Watt

    Name:   Trevor Watt
    Title:   Vice President


    HELLMAN & FRIEDMAN CAPITAL PARTNERS VIII, L.P.
    By:   Hellman & Friedman Investors VIII, L.P., its general partner
    By:   H&F Corporate Investors VIII, Ltd., its general partner
    By:  

    /s/ Trevor Watt

    Name:   Trevor Watt
    Title:   Vice President
    HELLMAN & FRIEDMAN CAPITAL PARTNERS VIII (PARALLEL), L.P.
    By:   Hellman & Friedman Investors VIII, L.P., its general partner
    By:   H&F Corporate Investors VIII, Ltd., its general partner
    By:  

    /s/ Trevor Watt

    Name:   Trevor Watt
    Title:   Vice President
    HFCP VIII (PARALLEL-A), L.P.
    By:   Hellman & Friedman Investors VIII, L.P., its general partner
    By:   H&F Corporate Investors VIII, Ltd., its general partner
    By:  

    /s/ Trevor Watt

    Name:   Trevor Watt
    Title:   Vice President
    H&F EXECUTIVES VIII, L.P.
    By:   Hellman & Friedman Investors VIII, L.P., its general partner
    By:   H&F Corporate Investors VIII, Ltd., its general partner
    By:  

    /s/ Trevor Watt

    Name:   Trevor Watt
    Title:   Vice President


    H&F ASSOCIATES VIII, L.P.
    By:   Hellman & Friedman Investors VIII, L.P., its general partner
    By:   H&F Corporate Investors VIII, Ltd., its general partner
    By:  

    /s/ Trevor Watt

    Name:   Trevor Watt
    Title:   Vice President


    EXHIBIT INDEX

     

    Exhibit

    Number

      

    Title

    1    Joint Filing Agreement dated February 12, 2021

     

    Get the next $PPD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PPD

    DatePrice TargetRatingAnalyst
    8/5/2021$47.50Neutral
    Credit Suisse
    More analyst ratings

    $PPD
    Financials

    Live finance-specific insights

    See more
    • PPD Announces Third Quarter 2021 Earnings Conference Call

      PPD, Inc. (NASDAQ:PPD), a leading global contract research organization, will host a conference call on Thursday, October 28, 2021, at 8 a.m. (U.S. Eastern Time) to discuss its third quarter 2021 financial results. Investors and other interested parties may listen to a live webcast of the conference call by logging on to the investors section of PPD's website at https://investors.ppd.com. An archived copy of the webcast will be available on the website after the call. In addition, the conference call can be accessed live over the phone by dialing +1 877 407 0784, or for international callers, +1 201 689 8560. A replay will be available after the call and can be accessed by dialing +1 844 5

      10/18/21 4:05:00 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization

      CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The data analysis indicates a vaccine efficacy of 94.1%. Safety data continue to accrue and the study continues to be monitored by an independent, NIH-appointed Data Safety Monitoring Board (DSMB). The Company also announced that today, Moderna plans to request an Emergency Use Authorization (EUA) f

      11/30/20 6:59:00 AM ET
      $MRNA
      $PPD
      $MCK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Other Pharmaceuticals

    $PPD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Credit Suisse resumed coverage on PPD with a new price target

      Credit Suisse resumed coverage of PPD with a rating of Neutral and set a new price target of $47.50

      8/5/21 6:25:35 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD downgraded by JP Morgan with a new price target

      JP Morgan downgraded PPD from Overweight to Neutral and set a new price target of $48.00

      4/28/21 10:25:55 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD downgraded by Jefferies

      Jefferies downgraded PPD from Buy to Hold

      4/20/21 8:11:33 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PPD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by PPD, Inc.

      SC 13G - PPD, Inc. (0001793294) (Subject)

      12/9/21 5:06:56 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed

      SC 13G - PPD, Inc. (0001793294) (Subject)

      2/12/21 4:19:09 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13G filed

      SC 13G - PPD, Inc. (0001793294) (Subject)

      2/12/21 6:11:58 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PPD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Saama Appoints Scott Rogers as Company's Chief Financial Officer

      Scott brings a unique combination of financial and clinical fused with growth experience to Saama New CFO appointment follows October announcement of $430M growth investment Saama Technologies, Inc. ("Saama") today announced that Scott Rogers, 17-year industry veteran, has been appointed as the company's Chief Financial Officer, effective January 31, 2022. In this position Scott is responsible for leading the company's global finance organization and will report to Saama Founder and CEO Suresh Katta. Scott comes to Saama with significant financial executive experience in clinical development, commercial growth, and financial reporting and compliance. He progressed rapidly through the

      2/2/22 8:00:00 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Thermo Fisher Scientific Completes Acquisition of PPD, Inc.

      WALTHAM, Mass., Dec. 8, 2021 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that it has completed its acquisition of PPD, Inc. (NASDAQ:PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion. "We are very excited to officially welcome our PPD colleagues to Thermo Fisher Scientific," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. "Expanding our value proposition for our biotech and pharmaceutical customers with the addition of PPD's leading clinical research services advances our work in bringing life-changing therapi

      12/8/21 8:45:00 AM ET
      $PPD
      $TMO
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Industrial Machinery/Components
      Industrials
    • PPD Named to 'Best Workplaces in Greater China' for Second Consecutive Year

      PPD, Inc. (NASDAQ:PPD) was named one of the "Best Workplaces in Greater China™ 2021" by Great Place to Work® for successfully creating an inclusive workplace experience for employees. PPD has more than 20 years of experience in the Asia-Pacific region, including providing a broad range of clinical development and laboratory services in Greater China. This is the second year PPD has received this recognition from Great Place to Work®, a global authority on high-trust, high-performance workplace cultures. "We remain committed to providing a healthy and open work environment for our employees, and this award shows that we continue to be successful in our efforts for yet another year," said D

      12/7/21 9:00:00 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PPD
    SEC Filings

    See more
    • SEC Form 15-12B filed by PPD, Inc.

      15-12B - PPD, Inc. (0001793294) (Filer)

      12/20/21 5:20:22 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 POS filed by PPD, Inc.

      S-8 POS - PPD, Inc. (0001793294) (Filer)

      12/8/21 4:16:02 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • PPD, Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Other Events, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - PPD, Inc. (0001793294) (Filer)

      12/8/21 4:12:04 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PPD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Carlyle Group Inc. disposed of $2,646,829,818 worth of shares (55,722,733 units at $47.50)

      4 - PPD, Inc. (0001793294) (Issuer)

      12/9/21 5:14:00 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: H&F Corporate Investors Viii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)

      4 - PPD, Inc. (0001793294) (Issuer)

      12/8/21 5:05:14 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 4: H&F Corporate Investors Vii, Ltd. sold $6,309,960,135 worth of shares (132,841,266 units at $47.50)

      4 - PPD, Inc. (0001793294) (Issuer)

      12/8/21 4:53:26 PM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $PPD
    Leadership Updates

    Live Leadership Updates

    See more
    • Saama Appoints Scott Rogers as Company's Chief Financial Officer

      Scott brings a unique combination of financial and clinical fused with growth experience to Saama New CFO appointment follows October announcement of $430M growth investment Saama Technologies, Inc. ("Saama") today announced that Scott Rogers, 17-year industry veteran, has been appointed as the company's Chief Financial Officer, effective January 31, 2022. In this position Scott is responsible for leading the company's global finance organization and will report to Saama Founder and CEO Suresh Katta. Scott comes to Saama with significant financial executive experience in clinical development, commercial growth, and financial reporting and compliance. He progressed rapidly through the

      2/2/22 8:00:00 AM ET
      $PPD
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care